aid: bitterroot-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/bitterroot-bio.png
name: Bitterroot Bio
description: 'Bitterroot Bio is a privately held, clinical-stage biotechnology company based in Palo
  Alto, California, pioneering the emerging field of cardio-immunology — the interplay between the immune
  system and cardiovascular disease. Its lead program, BRB-002, is a novel investigational immunomodulating
  protein therapy that targets CD47 to treat atherosclerotic cardiovascular disease (ASCVD) by acting on
  atherosclerotic plaque through the immunomodulation of macrophages, an approach distinct from current
  standards of care. Founded in 2021, the company is advancing BRB-002 through its MATADOR Phase 2a proof-of-concept
  study. Bitterroot Bio is a therapeutics developer and publishes no public developer API or programmatic
  surface; this profile captures its public web identity within the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/bitterroot-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Cardiovascular
- Cardio-Immunology
- Pharmaceuticals
- Clinical Trials
- Drug Development
- Palo Alto
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://brbio.com
- type: Blog
  url: https://brbio.com/category/press-release/
- type: PrivacyPolicy
  url: https://brbio.com/privacy-policy/
- type: TermsOfService
  url: https://brbio.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/bitterroot-bio
- type: DomainSecurity
  url: security/bitterroot-bio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence